CpG oligodeoxynucleotide preconditioning improves cardiac function after myocardial infarction via modulation of energy metabolism and angiogenesis

Deng Cheng Zhou, Yong Hui Su, Fu Qing Jiang, Jing Bo Xia, Hai Yan Wu, Zao Shang Chang, Wen Tao Peng, Guo Hua Song, Kyu Sang Park, Soo Ki Kim, Dong Qing Cai, Li Zheng, Xu Feng Qi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Unmethylated CpG oligodeoxynucleotide (CpG-ODN), a Toll-like receptor 9 (TLR9) ligand, has been shown to protect against myocardial ischemia/reperfusion injury. However, the potential effects of CpG-ODN on myocardial infarction (MI) induced by persistent ischemia remains unclear. Here, we investigated whether and how CpG-ODN preconditioning protects against MI in mice. C57BL/6 mice were treated with CpG-ODN by i.p. injection 2 hr prior to MI induction, and cardiac function, and histology were analyzed 2 weeks after MI. Both 1826-CpG and KSK-CpG preconditioning significantly improved the left ventricular (LV) ejection fraction (LVEF) and LV fractional shortening (LVFS) when compared with non-CpG controls. Histological analysis further confirmed the cardioprotection of CpG-ODN preconditioning. In vitro studies further demonstrated that CpG-ODN preconditioning increases cardiomyocyte survival under hypoxic/ischemic conditions by enhancing stress tolerance through TLR9-mediated inhibition of the SERCA2/ATP and activation of AMPK pathways. Moreover, CpG-ODN preconditioning significantly increased angiogenesis in the infarcted myocardium compared with non-CpG. However, persistent TLR9 activation mediated by lentiviral infection failed to improve cardiac function after MI. Although CpG-ODN preconditioning increased angiogenesis in vitro, both the persistent stimulation of CpG-ODN and stable overexpression of TLR9 suppressed the tube formation of cardiac microvascular endothelial cells. CpG-ODN preconditioning significantly protects cardiac function against MI by suppressing the energy metabolism of cardiomyocytes and promoting angiogenesis. Our data also indicate that CpG-ODN preconditioning may be useful in MI therapy.

Original languageEnglish
Pages (from-to)4245-4257
Number of pages13
JournalJournal of Cellular Physiology
Volume233
Issue number5
DOIs
Publication statusPublished - 2018 May

Fingerprint

Oligodeoxyribonucleotides
Energy Metabolism
Myocardial Infarction
Modulation
Toll-Like Receptor 9
Cardiac Myocytes
Chemical activation
Myocardial Reperfusion Injury
AMP-Activated Protein Kinases
Histology
Endothelial cells
Reperfusion Injury
Inbred C57BL Mouse
Stroke Volume
Myocardial Ischemia
Myocardium
Ischemia
Endothelial Cells
Adenosine Triphosphate
Ligands

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Zhou, Deng Cheng ; Su, Yong Hui ; Jiang, Fu Qing ; Xia, Jing Bo ; Wu, Hai Yan ; Chang, Zao Shang ; Peng, Wen Tao ; Song, Guo Hua ; Park, Kyu Sang ; Kim, Soo Ki ; Cai, Dong Qing ; Zheng, Li ; Qi, Xu Feng. / CpG oligodeoxynucleotide preconditioning improves cardiac function after myocardial infarction via modulation of energy metabolism and angiogenesis. In: Journal of Cellular Physiology. 2018 ; Vol. 233, No. 5. pp. 4245-4257.
@article{66d0ccacdf2a4dbb93485ab9b806e130,
title = "CpG oligodeoxynucleotide preconditioning improves cardiac function after myocardial infarction via modulation of energy metabolism and angiogenesis",
abstract = "Unmethylated CpG oligodeoxynucleotide (CpG-ODN), a Toll-like receptor 9 (TLR9) ligand, has been shown to protect against myocardial ischemia/reperfusion injury. However, the potential effects of CpG-ODN on myocardial infarction (MI) induced by persistent ischemia remains unclear. Here, we investigated whether and how CpG-ODN preconditioning protects against MI in mice. C57BL/6 mice were treated with CpG-ODN by i.p. injection 2 hr prior to MI induction, and cardiac function, and histology were analyzed 2 weeks after MI. Both 1826-CpG and KSK-CpG preconditioning significantly improved the left ventricular (LV) ejection fraction (LVEF) and LV fractional shortening (LVFS) when compared with non-CpG controls. Histological analysis further confirmed the cardioprotection of CpG-ODN preconditioning. In vitro studies further demonstrated that CpG-ODN preconditioning increases cardiomyocyte survival under hypoxic/ischemic conditions by enhancing stress tolerance through TLR9-mediated inhibition of the SERCA2/ATP and activation of AMPK pathways. Moreover, CpG-ODN preconditioning significantly increased angiogenesis in the infarcted myocardium compared with non-CpG. However, persistent TLR9 activation mediated by lentiviral infection failed to improve cardiac function after MI. Although CpG-ODN preconditioning increased angiogenesis in vitro, both the persistent stimulation of CpG-ODN and stable overexpression of TLR9 suppressed the tube formation of cardiac microvascular endothelial cells. CpG-ODN preconditioning significantly protects cardiac function against MI by suppressing the energy metabolism of cardiomyocytes and promoting angiogenesis. Our data also indicate that CpG-ODN preconditioning may be useful in MI therapy.",
author = "Zhou, {Deng Cheng} and Su, {Yong Hui} and Jiang, {Fu Qing} and Xia, {Jing Bo} and Wu, {Hai Yan} and Chang, {Zao Shang} and Peng, {Wen Tao} and Song, {Guo Hua} and Park, {Kyu Sang} and Kim, {Soo Ki} and Cai, {Dong Qing} and Li Zheng and Qi, {Xu Feng}",
year = "2018",
month = "5",
doi = "10.1002/jcp.26243",
language = "English",
volume = "233",
pages = "4245--4257",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "5",

}

CpG oligodeoxynucleotide preconditioning improves cardiac function after myocardial infarction via modulation of energy metabolism and angiogenesis. / Zhou, Deng Cheng; Su, Yong Hui; Jiang, Fu Qing; Xia, Jing Bo; Wu, Hai Yan; Chang, Zao Shang; Peng, Wen Tao; Song, Guo Hua; Park, Kyu Sang; Kim, Soo Ki; Cai, Dong Qing; Zheng, Li; Qi, Xu Feng.

In: Journal of Cellular Physiology, Vol. 233, No. 5, 05.2018, p. 4245-4257.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CpG oligodeoxynucleotide preconditioning improves cardiac function after myocardial infarction via modulation of energy metabolism and angiogenesis

AU - Zhou, Deng Cheng

AU - Su, Yong Hui

AU - Jiang, Fu Qing

AU - Xia, Jing Bo

AU - Wu, Hai Yan

AU - Chang, Zao Shang

AU - Peng, Wen Tao

AU - Song, Guo Hua

AU - Park, Kyu Sang

AU - Kim, Soo Ki

AU - Cai, Dong Qing

AU - Zheng, Li

AU - Qi, Xu Feng

PY - 2018/5

Y1 - 2018/5

N2 - Unmethylated CpG oligodeoxynucleotide (CpG-ODN), a Toll-like receptor 9 (TLR9) ligand, has been shown to protect against myocardial ischemia/reperfusion injury. However, the potential effects of CpG-ODN on myocardial infarction (MI) induced by persistent ischemia remains unclear. Here, we investigated whether and how CpG-ODN preconditioning protects against MI in mice. C57BL/6 mice were treated with CpG-ODN by i.p. injection 2 hr prior to MI induction, and cardiac function, and histology were analyzed 2 weeks after MI. Both 1826-CpG and KSK-CpG preconditioning significantly improved the left ventricular (LV) ejection fraction (LVEF) and LV fractional shortening (LVFS) when compared with non-CpG controls. Histological analysis further confirmed the cardioprotection of CpG-ODN preconditioning. In vitro studies further demonstrated that CpG-ODN preconditioning increases cardiomyocyte survival under hypoxic/ischemic conditions by enhancing stress tolerance through TLR9-mediated inhibition of the SERCA2/ATP and activation of AMPK pathways. Moreover, CpG-ODN preconditioning significantly increased angiogenesis in the infarcted myocardium compared with non-CpG. However, persistent TLR9 activation mediated by lentiviral infection failed to improve cardiac function after MI. Although CpG-ODN preconditioning increased angiogenesis in vitro, both the persistent stimulation of CpG-ODN and stable overexpression of TLR9 suppressed the tube formation of cardiac microvascular endothelial cells. CpG-ODN preconditioning significantly protects cardiac function against MI by suppressing the energy metabolism of cardiomyocytes and promoting angiogenesis. Our data also indicate that CpG-ODN preconditioning may be useful in MI therapy.

AB - Unmethylated CpG oligodeoxynucleotide (CpG-ODN), a Toll-like receptor 9 (TLR9) ligand, has been shown to protect against myocardial ischemia/reperfusion injury. However, the potential effects of CpG-ODN on myocardial infarction (MI) induced by persistent ischemia remains unclear. Here, we investigated whether and how CpG-ODN preconditioning protects against MI in mice. C57BL/6 mice were treated with CpG-ODN by i.p. injection 2 hr prior to MI induction, and cardiac function, and histology were analyzed 2 weeks after MI. Both 1826-CpG and KSK-CpG preconditioning significantly improved the left ventricular (LV) ejection fraction (LVEF) and LV fractional shortening (LVFS) when compared with non-CpG controls. Histological analysis further confirmed the cardioprotection of CpG-ODN preconditioning. In vitro studies further demonstrated that CpG-ODN preconditioning increases cardiomyocyte survival under hypoxic/ischemic conditions by enhancing stress tolerance through TLR9-mediated inhibition of the SERCA2/ATP and activation of AMPK pathways. Moreover, CpG-ODN preconditioning significantly increased angiogenesis in the infarcted myocardium compared with non-CpG. However, persistent TLR9 activation mediated by lentiviral infection failed to improve cardiac function after MI. Although CpG-ODN preconditioning increased angiogenesis in vitro, both the persistent stimulation of CpG-ODN and stable overexpression of TLR9 suppressed the tube formation of cardiac microvascular endothelial cells. CpG-ODN preconditioning significantly protects cardiac function against MI by suppressing the energy metabolism of cardiomyocytes and promoting angiogenesis. Our data also indicate that CpG-ODN preconditioning may be useful in MI therapy.

UR - http://www.scopus.com/inward/record.url?scp=85035049197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035049197&partnerID=8YFLogxK

U2 - 10.1002/jcp.26243

DO - 10.1002/jcp.26243

M3 - Article

C2 - 29057537

AN - SCOPUS:85035049197

VL - 233

SP - 4245

EP - 4257

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 5

ER -